10 completed, 5 recruiting, 3 terminated, 3 unknown. 23 Phase 1, 12 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 23 | Completed 10, Recruiting 5, Terminated 3, Unknown 3, Suspended 1, Withdrawn 1 |
| Phase 2 | 12 | Completed 4, Recruiting 3, Terminated 2, Suspended 1, Unknown 1, Withdrawn 1 |
Follow Metastasis: new trials by email Literature Review of Metastasis trials Research Report on Metastasis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02) Docetaxel, Ifinatamab Deruxtecan, Opevesostat - Castration-Resistant Prostatic Cancer, Metastasis | Phase 1 / Phase 2 | Recruiting | Merck Sharp & Dohme LLC | 360 | 2025-07-03 | 2026-10-09 |
| A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy Alintegimod, Ipilimumab, Nivolumab - Advanced Cancer, Advanced Solid Tumor | Phase 1 / Phase 2 | Recruiting | 7 Hills Pharma, LLC | 126 | 2024-08-23 | 2026-04-13 |
| Effect of Azeliragon Combined With Stereotactic Radiation Therapy in Patients With Brain Metastases Azeliragon, Stereotactic radiosurgery, Corticosteroid - Cancer, Metastasis | Phase 1 / Phase 2 | Suspended | Baptist Health South Florida | 46 | 2023-11-17 | 2026-06-16 |
| ONC201 and Atezolizumab in Obesity-Driven Endometrial Cancer Atezolizumab, ONC201 - Endometrial Cancer, Metastasis | Phase 1 | Recruiting | UNC Lineberger Comprehensive Cancer Center | 58 | 2023-10-23 | 2026-01-29 |
| Study of PAT in Patients With Solid Tumor Cancers Peptide Alarm Therapy (PAT) - Metastasis, Solid Tumor | Phase 1 | Recruiting | Masonic Cancer Center, University of Minnesota | 21 | 2023-05-19 | 2025-12-09 |
| A Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of AK114 AK114 - Advanced or Metastatic Solid Tumors, Malignancy | Phase 1 | Unknown | Akeso | 30 | 2022-03-15 | 2022-01-20 |
| Abemaciclib in Combination With Bicalutamide for Androgen Receptor-positive, HER2-negative Metastatic Breast Cancer Abemaciclib, Bicalutamide - Breast Cancer, Metastasis | Phase 1 / Phase 2 | Recruiting | Icahn School of Medicine at Mount Sinai | 42 | 2021-09-20 | 2026-04-13 |
| Trial of XRD-0394, a Kinase Inhibitor, in Combination With Palliative Radiotherapy in Advanced Cancer Patients XRD-0394, Palliative radiotherapy - Metastasis, Locally Advanced Solid Tumor | Phase 1 | Completed | XRad Therapeutics Inc | 12 | 2021-08-24 | 2024-01-11 |
| Encorafenib, Binimetinib and Palbociclib in BRAF-mutant Metastatic Melanoma CELEBRATE Binimetinib, Encorafenib, Palbociclib - Melanoma, Metastasis | Phase 1 / Phase 2 | Unknown | Peter MacCallum Cancer Centre, Australia | 78 | 2020-06-04 | 2024-01-05 |
| A Study Evaluating Safety and Therapeutic Activity of THOR-707 in Adult Subjects With Advanced or Metastatic Solid Tumors (THOR-707-101) THOR-707, Checkpoint inhibitor, anti-EGFR antibody - Metastasis | Phase 1 / Phase 2 | Terminated | Synthorx, Inc, a Sanofi company | 175 | 2019-06-20 | 2025-12-15 |
| Safety,Tolerability,and Efficacy of VCN-01 With Durvalumab in R/M Head and Neck Squamous Cell Carcinoma VCN-01, Durvalumab - Head and Neck Neoplasms, Carcinoma, Squamous Cell of Head and Neck | Phase 1 | Unknown | Institut Català d'Oncologia | 20 | 2019-03-20 | 2022-03-28 |
| Dose-escalation Study of IMC-001 in Subject With Metastatic or Locally-advanced Solid Tumors IMC-001 - Solid Tumor, Metastasis | Phase 1 | Completed | ImmuneOncia Therapeutics Inc. | 15 | 2018-03-22 | 2020-05-28 |
| Pembrolizumab + Idelalisib for Lung Cancer Study Pembrolizumab, Idelalisib - Non Small Cell Lung Cancer, Metastasis | Phase 1 / Phase 2 | Terminated | Asha Nayak | 4 | 2017-09-26 | 2024-02-28 |
| A Dose Escalation Study of SDX-7320 in Patients With Advanced Refractory or Late-Stage Solid Tumors SDX-7320 - Advanced Malignancy, Advanced Solid Tumors | Phase 1 | Completed | SynDevRx, Inc. | 32 | 2016-02-01 | 2020-01-27 |
| Combining Curcumin With FOLFOX Chemotherapy in Patients With Inoperable Colorectal Cancer Oral complex C3 curcumin + chemotherapy, Chemotherapy only - Colonic Cancer, Metastasis | Phase 1 / Phase 2 | Completed | University of Leicester | 41 | 2012-02-01 | 2020-01-31 |
| ECI301 and Radiation for Advanced or Metastatic Cancer Radiation Therapy, ECI301 - Cancer, Neoplasm Metastasis | Phase 1 | Terminated | National Cancer Institute (NCI) | 2 | 2011-09-06 | 2021-12-28 |
| Evaluation of the Safety and Efficacy of Oshadi D and Oshadi R for Cancer Treatment Oshadi D, Oshadi R - Tumor, Cancer | Phase 1 | Completed | Oshadi Drug Administration | 7 | 2011-01-01 | 2012-06-21 |
| Study of the Safety and Pharmacokinetics of Olaratumab (IMC-3G3) in Japanese Participants With Solid Tumors Olaratumab - Malignancy, Metastasis | Phase 1 | Completed | Eli Lilly and Company | 16 | 2010-09-01 | 2017-04-14 |
| FOLFOX/Bevacizumab/Hydroxychloroquine (HCQ) in Colorectal Cancer Hydroxychloroquine, Oxaliplatin, Leucovorin - Rectal Cancer, Colon Cancer | Phase 1 / Phase 2 | Completed | Abramson Cancer Center at Penn Medicine | 50 | 2010-09-01 | 2019-04-18 |
| Effect of Samarium on the Relief of Pain Due to Vertebral Metastases Samarium (153SM) - Cancer, Metastasis | Phase 1 / Phase 2 | Completed | New York Presbyterian Brooklyn Methodist Hospital | 29 | 2006-05-01 | 2019-08-26 |
Showing 20 of 23. Sign in to see all of them.
Neoplasm Metastasis (23) · Neoplasms (9) · Colorectal Neoplasms (4) · Recurrence (3) · Breast Neoplasms (2) · Carcinoma, Non-Small-Cell Lung (2) · Colonic Neoplasms (2) · Liver Neoplasms (2) · Melanoma (2) · Adenocarcinoma (1) · Agnosia (1) · Brain Neoplasms (1) · Carcinoma, Hepatocellular (1) · Carcinoma, Renal Cell (1) · Carcinosarcoma (1)
Neoplastic Processes (23) · Pathologic Processes (23) · Pathological Conditions, Signs and Symptoms (23) · Neoplasms (14) · Neoplasms by Site (13) · Colonic Diseases (5) · Digestive System Diseases (5) · Digestive System Neoplasms (5) · Gastrointestinal Diseases (5) · Gastrointestinal Neoplasms (5) · Intestinal Diseases (5) · Intestinal Neoplasms (5) · Neoplasms by Histologic Type (5) · Rectal Diseases (5) · Skin Diseases (4)
pembrolizumab (3) · Fluorouracil (2) · Oxaliplatin (2) · Adrenal Cortex Hormones (1) · Bevacizumab (1) · Cetuximab (1) · Cisplatin (1) · Curcumin (1) · Dexamethasone (1) · Docetaxel (1) · Drug Therapy (1) · Folfox protocol (1) · Hydroxychloroquine (1) · IMC-001 (1) · Ipilimumab (1)
7 Hills Pharma, LLC (1) · Abramson Cancer Center at Penn Medicine (1) · Akeso (1) · Asha Nayak (1) · Baptist Health South Florida (1) · Chugai Pharma USA (1) · Eli Lilly and Company (1) · Fondazione IRCCS Istituto Nazionale dei Tumori, Milano (1) · Icahn School of Medicine at Mount Sinai (1) · ImmuneOncia Therapeutics Inc. (1) · Institut Català d'Oncologia (1) · Masonic Cancer Center, University of Minnesota (1) · Medical College of Wisconsin (1) · Merck Sharp & Dohme LLC (1) · National Cancer Institute (NCI) (1)
United States (15) · Australia (4) · Spain (3) · Argentina (2) · Chile (2) · Israel (2) · South Korea (2) · United Kingdom (2) · Brazil (1) · Canada (1) · France (1) · Germany (1) · Ireland (1) · Italy (1) · Japan (1)
Alex HL Wong, MMedSc (1) · Amy Tiersten, MD (1) · Anne L Thomas, PhD FRCS (1) · Avishai Sella, Prof. (1) · Deborah E Citrin, M.D. (1) · Edward J Quebbeman, M. D. (1) · Grant McArthur, Prof (1) · Hani Ashamalla, MD, FCCP (1) · Lionel Lewis, MA, MB.Bch, MD (1) · Marcello Deraco, MD (1) · Melissa Geller, MD (1) · Minesh Mehta, M.D. (1)
PMID 24362862, PMID 25872567, PMID 25979230, PMID 27519353, PMID 31132111, PMID 33416261, PMID 34268711
2018 (1), 2023 (1), R21CA267584 (1)